Sort by
Refine Your Search
-
Listed
-
Category
-
Field
-
research team focused on advancing cancer care through cutting-edge computational and AI technologies. We develop innovative approaches that combine deep learning, computer vision, and bioinformatics
-
microorganisms, host cells and environmental factors affect health, disease and wellbeing, with expertise in microbiology, immunology, cellular and structural biology, data science, and bioinformatics. The Randall
-
post holder will work under the leadership of Programme Lead, Dr Sheeba Irshad, and in close collaboration with bioinformatics teams at the Institute of Cancer Research (ICR) and King’s College London
-
analytical and problem-solving abilities. Experience with scientific manuscript writing. Excellent communication and interpersonal skills. Experience with Bioinformatic approaches for sequence analyses
-
licence Experience in using statistical tools for bioinformatic analyses Downloading a copy of our Job Description Full details of the role and the skills, knowledge and experience required can be found in
-
patient outcomes with valuable healthcare data ; https://doi.org/10.1101/123299 ) The CogStack team benefits from sitting within a leading programme of clinical, health and bioinformatics at the South
-
also provide support to bioinformatic analyses and data management. The successful candidate should have experience with analysing genomic data, be willing to work as part of a team and to be open-minded
-
, travel for conferences and presentations, as well as contribute to academic publications. The post holder is expected to hold a PhD degree in Bioinformatics, Computer Science or other relevant discipline
-
experience: Essential criteria PhD awarded in genetic epidemiology, statistical genetics, bioinformatics or related discipline Postdoctoral research experience in genetic epidemiology, statistical genetics
-
, neuroimaging, neurophysiology, proteomics, transcriptomics, epigenomics, metabolomics, bioinformatics, cell models and animal models. First in man and Phase 2, 3 and 4 clinical trials are also strongly supported